Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Miriam Hospital
mi
from
Providence, RI
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Cancer Centers of the Carolinas - Easley
mi
from
Easley, SC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Cancer Centers of the Carolinas - Easley
mi
from
Easley, SC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Bon Secours St. Francis Health System
mi
from
Greenville, SC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Bon Secours St. Francis Health System
mi
from
Greenville, SC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Cancer Centers of the Carolinas - Grove Commons
mi
from
Greenville, SC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Cancer Centers of the Carolinas - Grove Commons
mi
from
Greenville, SC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Greenville Hospital Cancer Center
mi
from
Greenville, SC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Greenville Hospital Cancer Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
CCOP - Greenville
mi
from
Greenville, SC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
CCOP - Greenville
mi
from
Greenville, SC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Mountainview Medical
mi
from
Berlin Corners, VT
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Mountainview Medical
mi
from
Berlin Corners, VT
Click here to add this to my saved trials
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
A Randomized, Open Label, Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) When Administered in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  7/17/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
A Randomized, Open Label, Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) When Administered in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 7/17/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  7/18/2017
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 7/18/2017
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  7/18/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 7/18/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  7/18/2017
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 7/18/2017
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Click here to add this to my saved trials
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  7/18/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 7/18/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML
Status: Enrolling
Updated:  7/20/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML
Status: Enrolling
Updated: 7/20/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Prostate Embolization for Benign Prostatic Hyperplasia
Prostate Embolization for Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  7/20/2017
MedStar Georgetown University Hospital
mi
from
Washington, D.C.,
Prostate Embolization for Benign Prostatic Hyperplasia
Prostate Embolization for Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 7/20/2017
MedStar Georgetown University Hospital
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated:  7/20/2017
Novo Nordisk Investigational Site
mi
from
Torrance, CA
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated: 7/20/2017
Novo Nordisk Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated:  7/20/2017
Novo Nordisk Investigational Site
mi
from
Indianapolis, IN
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated: 7/20/2017
Novo Nordisk Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated:  7/20/2017
Novo Nordisk Investigational Site
mi
from
Iowa City, IA
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated: 7/20/2017
Novo Nordisk Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated:  7/20/2017
Novo Nordisk Investigational Site
mi
from
Baltimore, MD
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated: 7/20/2017
Novo Nordisk Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated:  7/20/2017
Novo Nordisk Investigational Site
mi
from
New York, NY
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated: 7/20/2017
Novo Nordisk Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated:  7/20/2017
Novo Nordisk Investigational Site
mi
from
Portland, OR
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated: 7/20/2017
Novo Nordisk Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated:  7/20/2017
Novo Nordisk Investigational Site
mi
from
Houston, TX
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated: 7/20/2017
Novo Nordisk Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated:  7/20/2017
Novo Nordisk Investigational Site
mi
from
Milwaukee, WI
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated: 7/20/2017
Novo Nordisk Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated:  7/20/2017
Novo Nordisk Investigational Site
mi
from
Camperdown,
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Status: Enrolling
Updated: 7/20/2017
Novo Nordisk Investigational Site
mi
from
Camperdown,
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
Tulane University
mi
from
New Orleans, LA
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
Tulane University
mi
from
New Orleans, LA
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
Wayne State University
mi
from
Detroit, MI
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
University of Texas Southwestern
mi
from
Dallas, TX
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
All Children's Research Institute
mi
from
Saint Petersburg, FL
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
All Children's Research Institute
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)
A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)
Status: Enrolling
Updated:  7/31/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)
A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)
Status: Enrolling
Updated: 7/31/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/1/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/1/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/1/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/1/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Costa Mesa, CA
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Miami, FL
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Orlando, FL
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Illinois Cancer Care
mi
from
Peoria, IL
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Kansas Cancer Center - Clinical Research Center
mi
from
Fairway, KA
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Kansas Cancer Center - Clinical Research Center
mi
from
Fairway, KA
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Maryland
mi
from
Baltimore, MD
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Mount Sinai Hospital
mi
from
New York, NY
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Oklahoma Peggy and Charles Stephenson Cancer Center
mi
from
Oklahoma City, OK
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Oklahoma Peggy and Charles Stephenson Cancer Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials